Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialLaura M. Spring, Aditya Bardia, Therese M. Mulvey et al.|Annals of Oncology|2023Cited by 75
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.Rachel O. Abelman, Laura M. Spring, Filipa Lynce et al.|Journal of Clinical Oncology|2025Cited by 11
Abstract PO3-13-09: Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: temporal dynamics and impact on clinical outcomesArielle J. Medford, Aditya Bardia, Douglas S. Micalizzi et al.|Cancer Research|2024Cited by 1